Sorrento Therapeutics Announces the Merger of Scilex and Semnur to Create a Global Leader in Non-Opioid Pain Management".
Semnur Pharmaceuticals has started a Phase 3 study for the treatment of lumbar radicular pain, commonly known as sciatica and has received fast track status from the FDA for the novel injectable gel formulation (SP-102) in development. Learn more
SP-102 is the first non-opioid novel injectable gel formulation in development for the treatment of lumbar radicular pain/sciatica, containing no neurotoxic preservatives, surfactants, solvents or particulates. Learn more
We are currently advancing a portfolio of non-opioid novel injectable drug candidates that have the potential to provide better and more persistent analgesia compared with existing therapies. Learn more